After considering the feedback from consultation, the Evaluation Committee has prepared a Final Evaluation Determination (FED) on Elosulfase alfa for treating mucopolysaccharidosis type IVa (re-evaluation of HST2) and submitted it to the Institute.
The FED has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FED has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FED may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England.
Please note that the appeal period for this appraisal will close at 5pm, Monday 4 April 2022.
This page was last updated: